公开(公告)号：WO2012120128A1

公开(公告)日：2012-09-13

申请号：PCT/EP2012/054149

申请日：2012-03-09

Applicant: CSL BEHRING GMBH ,  NOLTE, Marc ,  DICKNEITE, Gerhard ,  PRAGST, Ingo ,  SCHULTE, Stefan ,  ZEITLER, Stefan

Inventor： NOLTE, Marc ,  DICKNEITE, Gerhard ,  PRAGST, Ingo ,  SCHULTE, Stefan ,  ZEITLER, Stefan

IPC: A61K38/55 ,  A61K38/57 ,  A61K39/395 ,  C07K16/36 ,  A61P9/10

CPC classification number: A61K38/1767 ,  A61K31/727 ,  A61K38/16 ,  A61K38/556 ,  A61K38/57 ,  A61K38/58 ,  A61K39/3955 ,  A61K47/643 ,  A61K47/65 ,  A61L33/0041 ,  A61L33/0082 ,  A61L33/128 ,  A61L2300/252 ,  A61L2300/256 ,  A61L2300/42 ,  A61L2420/00 ,  C07K16/36 ,  C07K16/40 ,  C07K2317/76

Abstract: An inhibitor of FXII/FXIla for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIla is administered before and/or during and/or after said medical procedure.

Abstract translation: FXII / FXIla的抑制剂，用于在对人或动物受试者进行的医学过程期间和/或之后防止血栓的形成和/或稳定化，包括使所述人或动物受试者的血液与人造表面接触，其中所述抑制剂 FXII / FXIla在所述医疗程序之前和/或期间和/或之后施用。

公开(公告)号：WO2011035001A8

公开(公告)日：2012-04-19

申请号：PCT/US2010049078

申请日：2010-09-16

Applicant: GORE ENTERPRISE HOLDINGS INC ,  BIRAN ROY ,  CLAUDE CHARLES D ,  CLEEK ROBERT L ,  DRUMHELLER PAUL D ,  LI MEI ,  MARDIROSIAN NORA

Inventor： BIRAN ROY ,  CLAUDE CHARLES D ,  CLEEK ROBERT L ,  DRUMHELLER PAUL D ,  LI MEI ,  MARDIROSIAN NORA

IPC: A61L29/08 ,  A61L29/16 ,  A61L31/08 ,  A61L31/16

CPC classification number: A61L33/0011 ,  A61L27/54 ,  A61L29/16 ,  A61L31/022 ,  A61L31/048 ,  A61L31/10 ,  A61L31/16 ,  A61L33/08 ,  A61L33/128 ,  A61L2300/236 ,  A61L2300/42 ,  C08L27/12

Abstract: The present invention relates to immobilized biologically active entities that retain a significant biological activity following manipulation. The invention also comprises a medical substrate comprising a heparin entity bound onto a substrate via at least one heparin molecule, wherein said bound heparin entity is heparinase-1 sensitive.

Abstract translation: 本发明涉及在操作后保留显着的生物活性的固定的生物活性物质。 本发明还包括包含通过至少一个肝素分子结合到底物上的肝素实体的医用底物，其中所述结合的肝素实体是肝素酶-1敏感的。

公开(公告)号：WO2007098114A2

公开(公告)日：2007-08-30

申请号：PCT/US2007/004283

申请日：2007-02-16

Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES ,  VAN DYKE, Mark E.

Inventor： VAN DYKE, Mark E.

IPC: A61K38/39

CPC classification number: A61L33/128 ,  A61K38/1748 ,  A61L15/32 ,  A61L26/0047 ,  A61L27/227 ,  A61L27/34 ,  A61L27/54 ,  A61L29/048 ,  A61L29/085 ,  A61L29/16 ,  A61L31/047 ,  A61L31/10 ,  A61L31/16 ,  A61L33/0041 ,  A61L2300/42 ,  A61L2300/424 ,  C07K1/36 ,  C07K14/4741 ,  C08L89/04

Abstract: Disclosed are optimized keratin preparations for use in medical applications. Methods to produce optimized keratin preparations are provided for use in biomedical applications, particularly for the treatment of bleeding, and for the treatment of wounds. Also disclosed are surgical or paramedic aids comprising a substrate with keratin preparations provided thereon, and kits comprising keratin derivatives packaged in sterile form.

Abstract translation: 公开了用于医​​疗应用的优化的角蛋白制剂。 提供生产优化的角蛋白制剂的方法用于生物医学应用，特别是用于治疗出血和用于治疗伤口。 还公开了包括其上提供有角蛋白制剂的底物的外科或辅助辅助辅助剂以及包含无菌形式的角蛋白衍生物的试剂盒。

公开(公告)号：WO0074701A3

公开(公告)日：2001-08-30

申请号：PCT/US0040125

申请日：2000-06-05

Applicant: UNIV LELAND STANFORD JUNIOR ,  CELLGATE INC

Inventor： COOKE JOHN P ,  FATHMAN GARRISON C ,  ROTHBARD JONATHAN B ,  UEMURA SHIRO ,  ROBBINS ROBERT C ,  KOWN MURRAY H

IPC: A61K38/00 ,  A61K38/03 ,  A61K38/08 ,  A61K38/10 ,  A61K38/16 ,  A61L27/22 ,  A61L27/34 ,  A61L33/12 ,  A61P7/04 ,  A61P9/14 ,  A61P43/00 ,  C07K2/00 ,  A61L33/00

CPC classification number: A61L33/12 ,  A61K38/03 ,  A61K38/08 ,  A61K38/10 ,  A61K38/16 ,  A61L27/227 ,  A61L27/34 ,  A61L33/128 ,  C08L77/04

Abstract: Cardiovascular cell proliferation in a blood vessel subjected to trauma, such as angioplasty, vascular graft, anastomosis, or organ transplant, can be inhibited by contacting the vessel with a polymer consisting of from 6 to about 30 amino acid subunits, where at least 50 % of the subunits are arginine, and the polymer contains at least six contiguous arginine subunits. Exemplary polymers for this purpose include arginine homopolymers 7 to 15 subunits in length.

Abstract translation: 血管成形术，血管移植物，吻合或器官移植等受创伤的血管中的心血管细胞增殖可以通过使血管与由6个至约30个氨基酸亚基组成的聚合物接触来抑制，其中至少50％ 的亚基是精氨酸，并且聚合物含有至少六个连续的精氨酸亚基。 用于此目的的示例性聚合物包括长度为7至15个亚基的精氨酸均聚物。

公开(公告)号：WO98052623A1

公开(公告)日：1998-11-26

申请号：PCT/US1998/010404

申请日：1998-05-20

IPC: A61B17/12 ,  A61L27/34 ,  A61L31/10 ,  A61L33/12 ,  A61L27/00 ,  A61L31/00

CPC classification number: A61L33/128 ,  A61B17/12022 ,  A61B17/1215 ,  A61B17/12181 ,  A61L27/34 ,  A61L31/10 ,  A61L33/122 ,  A61L33/126 ,  C08L89/00 ,  C08L89/06

Abstract: Ion-implanted protein-coated occlusion coils are described which have essentially the same dimensions as untreated coils and exhibit altered surface properties, e.g., thrombogenicity, endothelial cellular migration and adhesion, relative to untreated coils thus making them particularly useful in treating wide-necked brain aneurysms.

Abstract translation: 描述了离子注入的蛋白质包被的闭塞线圈，其具有与未处理的线圈基本上相同的尺寸，并且相对于未处理的线圈表现出改变的表面性质，例如血栓形成，内皮细胞迁移和粘附，因此使得它们特别可用于治疗宽颈大脑 动脉瘤。

公开(公告)号：WO1992005748A1

公开(公告)日：1992-04-16

申请号：PCT/US1991005352

申请日：1991-07-29

Applicant: NEW ENGLAND DEACONESS HOSPITAL CORPORATION

Inventor： NEW ENGLAND DEACONESS HOSPITAL CORPORATION ,  ITO, Ralph, K. ,  LOGERFO, Frank, W.

IPC: A61F02/00

CPC classification number: A61L33/0029 ,  A61K38/58 ,  A61K47/6425 ,  A61L33/128 ,  Y10S530/81 ,  Y10S530/812 ,  Y10S530/813

Abstract: Disclosed is a soluble, biocompatible, pharmacological agent for inhibiting thrombin generation and thrombus formation, and methods for producing the same. The pharmacological agent or conjugate includes a soluble, biocompatible carrier and a thrombogenesis inhibitor immobilized thereto via a component of the carrier which binds the inhibitor. The thrombogenesis inhibitor is hirudin, or an active analog or active fragment thereof. The thrombogenesis inhibitor may be bound to the component of the carrier via a bifunctional cross-linking reagent.

Abstract translation: 公开了用于抑制凝血酶产生和血栓形成的可溶性，生物相容性药理学试剂及其制备方法。 药理学试剂或缀合物包括通过结合抑制剂的载体组分固定于其上的可溶性生物相容性载体和血栓发生抑制剂。 血栓形成抑制剂是水蛭素或其活性的类似物或活性片段。 血栓形成抑制剂可以通过双功能交联剂与载体的组分结合。

公开(公告)号：WO2011035001A2

公开(公告)日：2011-03-24

申请号：PCT/US2010/049078

申请日：2010-09-16

Applicant: GORE ENTERPRISE HOLDING, INC. ,  BIRAN, Roy ,  CLAUDE, Charles, D. ,  CLEEK, Robert, L. ,  DRUMHELLER, Paul, D. ,  LI, Mei ,  MARDIROSIAN, Nora

Inventor： BIRAN, Roy ,  CLAUDE, Charles, D. ,  CLEEK, Robert, L. ,  DRUMHELLER, Paul, D. ,  LI, Mei ,  MARDIROSIAN, Nora

IPC: A61L29/08 ,  A61L29/16 ,  A61L31/08 ,  A61L31/16

CPC classification number: A61L33/0011 ,  A61L27/54 ,  A61L29/16 ,  A61L31/022 ,  A61L31/048 ,  A61L31/10 ,  A61L31/16 ,  A61L33/08 ,  A61L33/128 ,  A61L2300/236 ,  A61L2300/42 ,  C08L27/12

Abstract: The present invention relates to immobilized biologically active entities that retain a significant biological activity following manipulation. The invention also comprises a medical substrate comprising a heparin entity bound onto a substrate via at least one heparin molecule, wherein said bound heparin entity is heparinase-1 sensitive.

Abstract translation: 本发明涉及在操作后保留显着的生物活性的固定的生物活性物质。 本发明还包括包含通过至少一个肝素分子结合到底物上的肝素实体的医用底物，其中所述结合的肝素实体是肝素酶-1敏感的。

公开(公告)号：WO2005023292A1

公开(公告)日：2005-03-17

申请号：PCT/US2004/028746

申请日：2004-09-03

Applicant: THE GENERAL HOSPITAL CORPORATION ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  LOMPR, Anne-Marie ,  LIPSKAIA, Larissa ,  MONTE, Federica, Del ,  HAJJAR, Roger, J.

Inventor： LOMPR, Anne-Marie ,  LIPSKAIA, Larissa ,  MONTE, Federica, Del ,  HAJJAR, Roger, J.

IPC: A61K38/46

CPC classification number: C12N15/86 ,  A61K38/00 ,  A61K48/00 ,  A61K48/005 ,  A61L33/128 ,  C12N9/14 ,  C12N2710/10343 ,  C12Y306/03008

Abstract: Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel.

Abstract translation: 可以通过向受试者的组织（例如血管）施用增加SERCA活性的药物来治疗受试者的再狭窄。 例如，可以将涂有该药剂的支架引入血管。

公开(公告)号：WO00050106A2

公开(公告)日：2000-08-31

申请号：PCT/EP2000/001497

申请日：2000-02-24

IPC: A61L33/08 ,  A61L33/12 ,  A61L33/18 ,  A61L33/00

CPC classification number: A61L33/128 ,  A61L33/08 ,  A61L33/18

Abstract: The invention relates to hemocompatible surfaces, characterized in that they contain materials and that components of the outer layer of blood cells and/or mesothelial cells are deposited on and/or introduced into the surface of said materials. The invention also relates to a method for preparing hemocompatible surfaces and to their use in numerous areas of the health sector, such as medicine, dentistry, surgery, cosmetics or in fields relating to blood, tissue and/or other body fluids.

Abstract translation: 本发明涉及血液相容性的表面，其特征在于它们含有的材料和上和/或至多血细胞和/或间皮细胞和/外层的这些材料成分的表面上或者被引入。 此外，本发明涉及用于制备血液相容的表面和其在卫生部门的广泛领域使用，在医学，牙科手术，化妆品或在与血液，组织和/或其它体液接触相关联的区域的处理。

公开(公告)号：WO99062395A3

公开(公告)日：2000-01-27

申请号：PCT/FI1999/000473

申请日：1999-06-01

IPC: A61L29/08 ,  A61L31/10 ,  A61L33/12 ,  A61L33/00 ,  A61L27/00 ,  A61M16/00 ,  A61M25/00

CPC classification number: A61L33/128 ,  A61L29/085 ,  A61L31/10 ,  A61L29/048 ,  A61L29/04 ,  A61L29/02 ,  A61L31/047 ,  A61L31/04 ,  A61L31/026 ,  A61L31/022 ,  C08L89/00

Abstract: The present invention is related to a method for preventing the clogging of medicinal drainage or ventilation tubes, comprising coating the surface of said ventilation tubes with anticlogging substances, especially human serum albumin. The medicinal ventilation tubes are rigid, semirigid and/or elastic tubes, such as tympanostomy tubes, paranasal sinus drainage tubes, thracheostomy tubes, gastric tubes, urinary catheters, wound drains and voice prosthesis tubes made of plastics, silicons, metals, hydroxylapatits, etc. The use of the anticlogging substances for manufacturing surface coated medicinal ventilation tubes for treatment of diseases requiring ventilation and/or drainage is also described.

Abstract translation: 本发明涉及一种用于防止药用排水管或通气管堵塞的方法，其特征在于，包括用防龋物质，特别是人血清白蛋白涂覆所述通气管的表面。 药用通气管是刚性，半刚性和/或弹性管，如鼓膜造口管，鼻旁窦引流管，气管造口管，胃管，导尿管，伤口排水管和由塑料，硅，金属，羟基磷灰石等制成的声音假体管 还描述了用于制造用于治疗需要通气和/或引流的疾病的表面包衣药物通气管的防龋物质的用途。